Evidence map›Paper›PMID 35306521›Full record

ArticleScientific reports2022

End-point RT-PCR based on a conservation landscape for SARS-COV-2 detection.

Armando Cruz-Rangel, Laura Gómez-Romero, Mireya Cisneros-Villanueva, G de Anda Jáuregui, Victor Luna-Pineda, Alberto Cedro-Tanda, Abraham Campos-Romero, Alfredo Mendoza-Vargas, J P Reyes-Grajeda, Alfredo Hidalgo-Miranda and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Armando Cruz-Rangel *Biochemistry of Chronic Diseases Laboratory, National Institute of Genomic Medicine, INMEGEN, Mexico City, Mexico.
Laura Gómez-Romero *Computational Genomics Department, National Institute of Genomic Medicine, INMEGEN, Mexico City, Mexico.
Mireya Cisneros-VillanuevaCancer Genomics Laboratory, National Institute of Genomic Medicine, INMEGEN, Mexico City, Mexico.
G de Anda JáureguiComputational Genomics Department, National Institute of Genomic Medicine, INMEGEN, Mexico City, Mexico.
Victor Luna-PinedaResearch Unit in Immunology and Proteomics, COVID-19 Research Laboratory, Children's Hospital of Mexico "Federico Gómez", Mexico City, Mexico.
Alberto Cedro-TandaNational Institute of Genomic Medicine, INMEGEN, Periférico Sur 4809, Arenal Tepepan, Tlalpan, 14610, Mexico City, Mexico.
Abraham Campos-RomeroInnovation and Research Department, Salud Digna, Culiacan, Sinaloa, Mexico.
Alfredo Mendoza-VargasSequencing Unit, National Institute of Genomic Medicine, INMEGEN, Mexico City, Mexico.
J P Reyes-GrajedaBiochemistry of Chronic Diseases Laboratory, National Institute of Genomic Medicine, INMEGEN, Mexico City, Mexico.
Alfredo Hidalgo-MirandaCancer Genomics Laboratory, National Institute of Genomic Medicine, INMEGEN, Mexico City, Mexico.
COVID-19 Consortium INMEGEN
Luis A HerreraNational Institute of Genomic Medicine, INMEGEN, Periférico Sur 4809, Arenal Tepepan, Tlalpan, 14610, Mexico City, Mexico. lherrera@inmegen.gob.mx.
Felipe Vadillo-OrtegaUnidad de Vinculación de la Facultad de Medicina, UNAM en el INMEGEN, Periférico Sur 4809, Arenal Tepepan, Tlalpan, 14610, Mexico City, Mexico. fvadillo@inmegen.gob.mx.
National Institute of Genomic Medicine · MXMSD (Mexico) · MXConsejo Nacional de Humanidades, Ciencias y Tecnologías · MXHospital Infantil de México Federico Gómez · MXInstituto Nacional de Cancerología · MXInstituto Tecnológico de Culiacán · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

End-point RT-PCR is a suitable alternative diagnostic technique since it is cheaper than RT-qPCR tests and can be implemented on a massive scale in low- and middle-income countries. In this work, a bioinformatic approach to guide the design of PCR primers was developed, and an alternative diagnostic test based on end-point PCR was designed. End-point PCR primers were designed through conservation analysis based on kmer frequency in SARS-CoV-2 and human respiratory pathogen genomes. Highly conserved regions were identified for primer design, and the resulting PCR primers were used to amplify 871 nasopharyngeal human samples with a previous RT-qPCR based SARS-CoV-2 diagnosis. The diagnostic test showed high accuracy in identifying SARS-CoV-2-positive samples including B.1.1.7, P.1, B.1.427/B.1.429 and B.1.617.2/ AY samples with a detection limit of 7.2 viral copies/µL. In addition, this test could discern SARS-CoV-2 infection from other viral infections with COVID-19-like symptomatology. The designed end-point PCR diagnostic test to detect SARS-CoV-2 is a suitable alternative to RT-qPCR. Since the proposed bioinformatic approach can be easily applied in thousands of viral genomes and over highly divergent strains, it can be used as a PCR design tool as new SARS-CoV-2 variants emerge. Therefore, this end-point PCR test could be employed in epidemiological surveillance to detect new SARS-CoV-2 variants as they emerge and propagate.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansReverse Transcriptase Polymerase Chain ReactionRNA, ViralRNA, Viral

Identifiers

PMID35306521
PMCPMC8933765
OpenAlexW4220965268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.